Deep Track Capital’s Edgewise Therapeutics EWTX Stock Holding History

Deep Track Capital’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,400,000	Closed	-$30.8M	–	71
2025 Q1	$30.8M	Buy	1,400,000 +689,579	+97%	+$18.1M	1%	27
2024 Q4	$19M	Sell	710,421 -390,115	-35%	-$12.4M	0.71%	38
2024 Q3	$29.4M	Buy	1,100,536 +914,150	+490%	+$18.2M	0.93%	35
2024 Q2	$3.36M	Buy	+186,386	New	+$3.25M	0.1%	61
2024 Q1	–	Sell	-2,537,176	Closed	-$27.8M	–	71
2023 Q4	$27.8M	Sell	2,537,176 -212,824	-8%	-$1.49M	0.93%	40
2023 Q3	$15.8M	Hold	2,750,000	–	–	0.61%	44
2023 Q2	$21.3M	Sell	2,750,000 -318,259	-10%	-$2.68M	0.99%	29
2023 Q1	$20.5M	Sell	3,068,259 -306,135	-9%	-$2.84M	0.84%	36
2022 Q4	$30.2M	Hold	3,374,394	–	–	1.27%	28
2022 Q3	$33.2M	Buy	+3,374,394	New	+$34.1M	1.52%	25

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deep Track Capital's EWTX Position: Q2 2025 in Review

Deep Track Capital sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 1,400,000 shares — an estimated $30.8M sold.

Deep Track Capital first reported a position in EWTX in Q3 2022 and held it in 10 quarters. The position peaked at $33.2M in Q3 2022. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

Deep Track Capital reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
Deep Track Capital sold 1,400,000 Edgewise Therapeutics shares in Q2 2025, an estimated $30.8M.
Deep Track Capital first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 10 quarters.
Deep Track Capital's Edgewise Therapeutics position peaked at $33.2M in Q3 2022.
178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Deep Track Capital's 13F filing for Q2 2025, filed 14 Aug 2025.